lunedì, 20 marzo 2023
8 Febbraio 2019

FDA Approves Caplacizumab-yhdp in Acquired Thrombotic Thrombocytopenic Purpura

February 6, 2019 – The FDA has approved the nanobody caplacizumab-yhdp in combination with plasma exchange and immunosuppression for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), making it the first FDA-approved therapy indicated for this patient population. The approval is based on findings from the pivotal phase III HERCULES trial, in which the caplacizumab-yhdp regimen led to a significantly shorter … (leggi tutto)